Marina Galperina
It finally happened.
According to the FDA, there is no longer a shortage of semaglutide, the active ingredient in the wildly popular Ozempic and Wegovy — a very bad omen for the countless telehealth and pharmacy businesses selling “compounded” versions of the diabetes and weight-loss drug. The FDA has clarified that state-licensed and out-sourcing operations have to cease production of the “compounded” medication by April 22nd and May 22nd, respectively.
The Ozempic Shortage Is Over
[wired.com]